PE20191546A1 - Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb - Google Patents

Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb

Info

Publication number
PE20191546A1
PE20191546A1 PE2019001290A PE2019001290A PE20191546A1 PE 20191546 A1 PE20191546 A1 PE 20191546A1 PE 2019001290 A PE2019001290 A PE 2019001290A PE 2019001290 A PE2019001290 A PE 2019001290A PE 20191546 A1 PE20191546 A1 PE 20191546A1
Authority
PE
Peru
Prior art keywords
cdr
seq
binding
antigen
domain
Prior art date
Application number
PE2019001290A
Other languages
English (en)
Inventor
Christina Claus
Christian Klein
Pablo Umana
Wei Xu
Koller Claudia Ferrara
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61024728&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191546(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20191546A1 publication Critical patent/PE20191546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G5/00—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators
    • G09G5/36—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of a graphic pattern, e.g. using an all-points-addressable [APA] memory
    • G09G5/37—Details of the operation on graphic patterns
    • G09G5/377—Details of the operation on graphic patterns for mixing or overlaying two or more graphic patterns
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N9/00—Details of colour television systems
    • H04N9/12—Picture reproducers
    • H04N9/31—Projection devices for colour picture display, e.g. using electronic spatial light modulators [ESLM]
    • H04N9/3102—Projection devices for colour picture display, e.g. using electronic spatial light modulators [ESLM] using two-dimensional electronic spatial light modulators
    • H04N9/312—Driving therefor
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N9/00—Details of colour television systems
    • H04N9/12—Picture reproducers
    • H04N9/31—Projection devices for colour picture display, e.g. using electronic spatial light modulators [ESLM]
    • H04N9/3179—Video signal processing therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0257—Reduction of after-image effects
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/04—Maintaining the quality of display appearance
    • G09G2320/043—Preventing or counteracting the effects of ageing
    • G09G2320/046—Dealing with screen burn-in prevention or compensation of the effects thereof
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/04—Maintaining the quality of display appearance
    • G09G2320/043—Preventing or counteracting the effects of ageing
    • G09G2320/048—Preventing or counteracting the effects of ageing using evaluation of the usage time
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/06—Adjustment of display parameters
    • G09G2320/0606—Manual adjustment
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2354/00—Aspects of interface with display user

Abstract

Referido a una molecula de union a antigeno biespecifica, que comprende al menos un dominio de union al antigeno capaz de unirse de manera especifica a 4-1BB, al menos un dominio de union al antigeno capaz de unirse a un antigeno de celula diana y un dominio Fc. Dicho dominio de union a 4-1BB, comprende una region variable de la cadena pesada, que comprende (i) CDR-H1 de SEQ ID NO: 1, (ii) CDR-H2 de SEQ ID NO: 2 y (iii) CDR-H3 de SEQ ID NO: 3; y una region variable de cadena ligera, que comprende (iv) CDR-L1 de SEQ ID NO: 4, (v) CDR -L2 de SEQ ID NO: 5, y (vi) CDR-L3 de SEQ ID NO: 6. El antigeno de celula diana se selecciona entre la proteina de activacion de fibroblastos (FAP), proteoglucano de sulfato de condroitina asociado a melanoma (MCSP), receptor de factor de crecimiento epidermico (EGFR), antigeno carcinoembrionario (CEA), CD19, CD20 o CD33. El dominio Fc de IgG formado por una primera y segunda subunidad capaces de asociarse de manera estable. Dicha molecula es util para el tratamiento de infecciones y cancer. Tambien se refiere a un polinucleotido, una celula huesped que codifica dicho anticuerpo y una composicion farmaceutica que comprende dicho anticuerpo.
PE2019001290A 2017-01-03 2018-01-02 Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb PE20191546A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17150150 2017-01-03
EP17164224 2017-03-31
PCT/EP2018/050024 WO2018127473A1 (en) 2017-01-03 2018-01-02 Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9

Publications (1)

Publication Number Publication Date
PE20191546A1 true PE20191546A1 (es) 2019-10-24

Family

ID=61024728

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001290A PE20191546A1 (es) 2017-01-03 2018-01-02 Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb

Country Status (19)

Country Link
US (2) US11447558B2 (es)
EP (1) EP3565843A1 (es)
JP (1) JP7122311B2 (es)
KR (1) KR20190099527A (es)
CN (1) CN110461873B (es)
AU (1) AU2018206138A1 (es)
BR (1) BR112019013189A2 (es)
CA (1) CA3047070A1 (es)
CL (1) CL2019001828A1 (es)
CO (1) CO2019007046A2 (es)
CR (1) CR20190309A (es)
IL (1) IL267607A (es)
MA (1) MA47200A (es)
MX (1) MX2019007795A (es)
PE (1) PE20191546A1 (es)
PH (1) PH12019501440A1 (es)
RU (1) RU2019123613A (es)
TW (1) TW201829469A (es)
WO (1) WO2018127473A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
EP3703821A2 (en) * 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Bispecific 2+1 contorsbodies
EP3818082A1 (en) * 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Novel bispecific agonistic 4-1bb antigen binding molecules
US20200048350A1 (en) * 2018-07-24 2020-02-13 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7221379B2 (ja) 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
EP3861025A1 (en) * 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
MY198034A (en) 2018-12-21 2023-07-27 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
CN113166265A (zh) * 2019-08-12 2021-07-23 天境生物科技(上海)有限公司 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
BR112022021447A2 (pt) * 2020-05-19 2022-12-13 Boehringer Ingelheim Int Moléculas de ligação para o tratamento de câncer
AU2021291011A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and CD19
TW202246351A (zh) * 2021-02-08 2022-12-01 美商恩格姆生物製藥公司 Htra1結合劑及其使用方法
WO2022243261A1 (en) * 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
CN117616049A (zh) * 2021-08-24 2024-02-27 江苏恒瑞医药股份有限公司 Fap/cd40结合分子及其医药用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024042105A1 (en) * 2022-08-26 2024-02-29 Merck Patent Gmbh Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
WO2024042104A1 (en) * 2022-08-26 2024-02-29 Merck Patent Gmbh Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE4106389A1 (de) 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
ES2528794T3 (es) * 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004253835B2 (en) 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1976880T3 (en) 2005-12-21 2016-09-26 Amgen Res (Munich) Gmbh Pharmaceutical compositions with resistance to soluble cea
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2012002006A1 (ja) 2010-06-29 2012-01-05 コニカミノルタエムジー株式会社 超音波診断装置及びプログラム
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
PT2691417T (pt) * 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
JP6441079B2 (ja) * 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
ES2900898T3 (es) * 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
WO2016030350A1 (en) 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
CA2980840A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
JP6947642B2 (ja) * 2015-05-18 2021-10-13 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん性融合ポリペプチド
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP6937746B2 (ja) 2015-10-02 2021-09-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
RU2761077C1 (ru) 2015-10-02 2021-12-03 Ф. Хоффманн-Ля Рош Аг Антитела против cd19 человека, обладающие высокой аффинностью
AU2016334623A1 (en) * 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN110087682B (zh) 2016-12-19 2023-12-15 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
BR112019017753A2 (pt) 2017-04-04 2020-04-07 Hoffmann La Roche molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
CA3079036A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists
EP3703821A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Bispecific 2+1 contorsbodies
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
TW202003561A (zh) 2018-03-13 2020-01-16 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
AR114284A1 (es) 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
EP3818082A1 (en) 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Novel bispecific agonistic 4-1bb antigen binding molecules
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
JP7221379B2 (ja) 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
CN113677403A (zh) 2019-04-12 2021-11-19 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
TW202115124A (zh) 2019-06-26 2021-04-16 瑞士商赫孚孟拉羅股份公司 結合至cea之新穎抗原結合分子
CA3162009A1 (en) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
KR20190099527A (ko) 2019-08-27
CL2019001828A1 (es) 2019-10-18
RU2019123613A (ru) 2021-02-05
TW201829469A (zh) 2018-08-16
CR20190309A (es) 2019-08-21
US20230045262A1 (en) 2023-02-09
CA3047070A1 (en) 2018-07-12
MA47200A (fr) 2019-11-13
WO2018127473A1 (en) 2018-07-12
BR112019013189A2 (pt) 2019-12-10
MX2019007795A (es) 2019-08-16
CN110461873A (zh) 2019-11-15
CO2019007046A2 (es) 2019-07-10
PH12019501440A1 (en) 2020-02-10
EP3565843A1 (en) 2019-11-13
CN110461873B (zh) 2023-05-12
AU2018206138A1 (en) 2019-07-11
JP2020504622A (ja) 2020-02-13
IL267607A (en) 2019-08-29
JP7122311B2 (ja) 2022-08-19
US20200190206A1 (en) 2020-06-18
US11447558B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
IL299221A (en) CD3 binding antibodies
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
RU2018146050A (ru) Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
HRP20200679T1 (hr) Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji
RU2018128414A (ru) Новое psma-связывающее антитело и его применения
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
PE20240096A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
RU2012142231A (ru) Антитела против csf-1r человека и их применение
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
RU2017122014A (ru) Антитела к c10orf54 и их применения
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
RU2012142230A (ru) Антитела против csf-1r человека и их применение
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
PE20120475A1 (es) Anticuerpos especificos para dkk-1
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
RU2017129236A (ru) Мультивалентные молекулы, содержащие dr5-связывающие домены
RS53405B (en) CXCR4 HUMANIZED ANTIBODIES FOR CANCER TREATMENT
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
UA108466C2 (en) Antibody antagonises c-Met